Volato Group's Annual Recurring Revenue Doubles to $3M
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 23 2026
0mins
Should l Buy SOAR?
Volato Group (SOAR) reported that Vaunt annual recurring revenue doubled to approximately $3M in Q1, while total debt declined by nearly 80% year-over-year to approximately $8.3M, positioning the Company below a key closing threshold for its proposed merger with M2i Global (MTWO). Volato has filed an updated registration statement on Form S-4 with the U.S. Securities and Exchange Commission in connection with its previously announced merger with M2i Global and has scheduled a special meeting of stockholders for April 20, 2026. The Company expects total debt to decline to approximately $8.3M as of March 31, representing a reduction of nearly 80% from $39.2M one year ago and positioning Volato below the $10M closing condition in the merger agreement.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SOAR?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SOAR
About SOAR
Volato Group Inc. is a private aviation company. It offers solutions in aviation software and on-demand flight access. Its two flagship platforms consist of Mission Control and Vaunt. Mission Control is the Company's flight management system. It supports operators in managing fractional ownership, charter, and other services. Its cloud-based software streamlines critical functions across flight scheduling, customer relationship management (CRM), crew management, and more. It provides tools to manage crew assignments, duty logs, scheduling, and compliance. It offers operators real-time dashboards with insights into key metrics, from fleet performance to customer satisfaction. The Vaunt platform connects travelers with available private flights, offering an option for on-demand travel. Vaunt offers a subscription service for private flights, giving members access to empty-leg flights. Its wholly owned subsidiaries include Volato, Inc., Fly Vaunt, LLC, and Gulf Coast Aviation, Inc.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Vaunt Revenue Doubles, Debt Reduced Significantly
- Revenue Doubling: Vaunt's annual recurring revenue reached approximately $3.0 million in Q1 2026, doubling year-over-year, which indicates strong market demand and scalability, likely driving further improvements in the company's overall performance.
- Significant Debt Reduction: The company's total debt decreased from $39.2 million a year ago to approximately $8.3 million, a nearly 80% reduction, positioning Volato below the $10 million closing condition in the merger agreement with M2i Global, enhancing the feasibility of the merger.
- Shareholder Vote Scheduled: Volato has scheduled a special meeting of shareholders for April 20, 2026, aimed at obtaining shareholder approval for the merger, a critical step that will lay the foundation for the company's future growth.
- Increased Market Participation: Since inception, Vaunt has achieved over 297,000 downloads and more than 2,200 flights, reflecting a significant increase in marketplace liquidity and operator participation, further solidifying its position as a recurring revenue platform.
See More
Volato Group Amends Aircraft Management Agreement to Sell IP Assets
- Asset Sale Agreement: Volato Group amended its Aircraft Management Services Agreement with flyExclusive to sell certain legacy intellectual property assets valued at approximately $1.3 million, to be paid in flyExclusive Class A common stock, demonstrating the company's flexibility in asset management.
- Intellectual Property Context: The assets being sold relate to intellectual property developed during earlier stages of Volato's technology initiatives, which, while not part of its current operating platforms, lay a foundation for future technological advancements, indicating the company's focus on its tech assets.
- Strategic Focus: Volato stated it will continue to evaluate opportunities to streamline its asset base, concentrating on the development of its core software platforms and its pending business combination with M2i Global, showcasing its strategic planning for future growth.
- Market Reaction: Following the amendment of the agreement, Volato's stock price surged 23.58% in premarket trading to $0.3962, reflecting a positive market response to the company's strategic adjustments.
See More
Volato Enters Asset Sale Agreement with flyExclusive
- Asset Sale Agreement: Volato has amended its Aircraft Management Services Agreement with flyExclusive to include the sale of legacy intellectual property assets valued at approximately $1.3 million, payable in FLYX Class A common stock, which is expected to generate additional value for shareholders.
- Technology Asset Optimization: The assets involved in this transaction relate to earlier technology initiatives and are not part of Volato's current operating platforms, allowing the company to better focus resources on the development of its core software platforms.
- Strategic Focus: Volato is evaluating opportunities to streamline its asset base and concentrate on strategic priorities, including the pending business combination with M2i Global, which will enhance its market position in the critical minerals sector.
- CEO Statement: Matt Liotta, Co-Founder and CEO of Volato, stated that this transaction reflects the company's disciplined approach to identifying and monetizing non-core assets, aiming to create incremental value for shareholders and demonstrating confidence in future growth.
See More
Zevra Therapeutics Reports Strong Q4 Earnings, Shares Surge
- Earnings Beat: Zevra Therapeutics reported Q4 earnings of $0.19 per share, significantly surpassing the analyst consensus of $0.05, indicating a notable improvement in profitability and boosting investor confidence.
- Sales Growth: The company achieved quarterly sales of $34.125 million, exceeding the analyst estimate of $28.051 million, reflecting strong product demand and solid market performance, which may drive future growth potential.
- Stock Surge: Following the earnings report, Zevra Therapeutics shares jumped 17.2% to $10.70 in pre-market trading, indicating a positive market reaction to the company's performance and potentially attracting more investor interest.
- Optimistic Market Outlook: This earnings beat not only enhances the company's short-term stock price but may also lay a foundation for long-term development, strengthening market confidence in its future growth prospects.
See More
Lisata Therapeutics to be Taken Private by Kuva Labs
- Acquisition Agreement: Lisata Therapeutics Inc has agreed to be taken private by Kuva Labs, offering shareholders $5.00 per share along with a $1.00 contingent value right per share, indicating recognition of the company's future potential.
- Significant Stock Surge: Following the acquisition announcement, Lisata Therapeutics' shares rose 20.3% in pre-market trading to $5.03, reflecting positive market reaction and increased investor confidence in the deal.
- Impact of Privatization: The acquisition will result in Lisata Therapeutics delisting from public markets, potentially providing the company with greater flexibility to focus on long-term strategic goals while mitigating the impact of market volatility on its operations.
- Market Dynamics Shift: The announcement of this deal has sparked interest in other related stocks, demonstrating investor enthusiasm for M&A activity in the biotech sector, which may influence future investment decisions and market trends.
See More
M2I GLOBAL - INITIATES PHASED PILOT SHIPMENT PROGRAM STARTING WITH CONTROLLED MATERIALS TRANSFERS FROM WESTERN AUSTRALIA TO THE UNITED STATES
Global Plans: A phased pilot shipment program is set to begin, focusing on the movement of controlled materials.
Material Movement: The initial phase will involve transporting materials from Western Australia to the United States.
See More
Vaunt Revenue Doubles, Debt Reduced Significantly
- Revenue Doubling: Vaunt's annual recurring revenue reached approximately $3.0 million in Q1 2026, doubling year-over-year, which indicates strong market demand and scalability, likely driving further improvements in the company's overall performance.
- Significant Debt Reduction: The company's total debt decreased from $39.2 million a year ago to approximately $8.3 million, a nearly 80% reduction, positioning Volato below the $10 million closing condition in the merger agreement with M2i Global, enhancing the feasibility of the merger.
- Shareholder Vote Scheduled: Volato has scheduled a special meeting of shareholders for April 20, 2026, aimed at obtaining shareholder approval for the merger, a critical step that will lay the foundation for the company's future growth.
- Increased Market Participation: Since inception, Vaunt has achieved over 297,000 downloads and more than 2,200 flights, reflecting a significant increase in marketplace liquidity and operator participation, further solidifying its position as a recurring revenue platform.
See More
Volato Group Amends Aircraft Management Agreement to Sell IP Assets
- Asset Sale Agreement: Volato Group amended its Aircraft Management Services Agreement with flyExclusive to sell certain legacy intellectual property assets valued at approximately $1.3 million, to be paid in flyExclusive Class A common stock, demonstrating the company's flexibility in asset management.
- Intellectual Property Context: The assets being sold relate to intellectual property developed during earlier stages of Volato's technology initiatives, which, while not part of its current operating platforms, lay a foundation for future technological advancements, indicating the company's focus on its tech assets.
- Strategic Focus: Volato stated it will continue to evaluate opportunities to streamline its asset base, concentrating on the development of its core software platforms and its pending business combination with M2i Global, showcasing its strategic planning for future growth.
- Market Reaction: Following the amendment of the agreement, Volato's stock price surged 23.58% in premarket trading to $0.3962, reflecting a positive market response to the company's strategic adjustments.
See More
Volato Enters Asset Sale Agreement with flyExclusive
- Asset Sale Agreement: Volato has amended its Aircraft Management Services Agreement with flyExclusive to include the sale of legacy intellectual property assets valued at approximately $1.3 million, payable in FLYX Class A common stock, which is expected to generate additional value for shareholders.
- Technology Asset Optimization: The assets involved in this transaction relate to earlier technology initiatives and are not part of Volato's current operating platforms, allowing the company to better focus resources on the development of its core software platforms.
- Strategic Focus: Volato is evaluating opportunities to streamline its asset base and concentrate on strategic priorities, including the pending business combination with M2i Global, which will enhance its market position in the critical minerals sector.
- CEO Statement: Matt Liotta, Co-Founder and CEO of Volato, stated that this transaction reflects the company's disciplined approach to identifying and monetizing non-core assets, aiming to create incremental value for shareholders and demonstrating confidence in future growth.
See More
Zevra Therapeutics Reports Strong Q4 Earnings, Shares Surge
- Earnings Beat: Zevra Therapeutics reported Q4 earnings of $0.19 per share, significantly surpassing the analyst consensus of $0.05, indicating a notable improvement in profitability and boosting investor confidence.
- Sales Growth: The company achieved quarterly sales of $34.125 million, exceeding the analyst estimate of $28.051 million, reflecting strong product demand and solid market performance, which may drive future growth potential.
- Stock Surge: Following the earnings report, Zevra Therapeutics shares jumped 17.2% to $10.70 in pre-market trading, indicating a positive market reaction to the company's performance and potentially attracting more investor interest.
- Optimistic Market Outlook: This earnings beat not only enhances the company's short-term stock price but may also lay a foundation for long-term development, strengthening market confidence in its future growth prospects.
See More
Lisata Therapeutics to be Taken Private by Kuva Labs
- Acquisition Agreement: Lisata Therapeutics Inc has agreed to be taken private by Kuva Labs, offering shareholders $5.00 per share along with a $1.00 contingent value right per share, indicating recognition of the company's future potential.
- Significant Stock Surge: Following the acquisition announcement, Lisata Therapeutics' shares rose 20.3% in pre-market trading to $5.03, reflecting positive market reaction and increased investor confidence in the deal.
- Impact of Privatization: The acquisition will result in Lisata Therapeutics delisting from public markets, potentially providing the company with greater flexibility to focus on long-term strategic goals while mitigating the impact of market volatility on its operations.
- Market Dynamics Shift: The announcement of this deal has sparked interest in other related stocks, demonstrating investor enthusiasm for M&A activity in the biotech sector, which may influence future investment decisions and market trends.
See More
M2I GLOBAL - INITIATES PHASED PILOT SHIPMENT PROGRAM STARTING WITH CONTROLLED MATERIALS TRANSFERS FROM WESTERN AUSTRALIA TO THE UNITED STATES
Global Plans: A phased pilot shipment program is set to begin, focusing on the movement of controlled materials.
Material Movement: The initial phase will involve transporting materials from Western Australia to the United States.
See More
